



# Evidence reviews – April 2022

Evidence review

Published: 27 April 2022

[www.nice.org.uk](http://www.nice.org.uk)

The following documents contain the evidence that was used to develop the recommendations:

- [Prediction of second seizure](#)
- [Modifiable risk factors for a second seizure](#)
- [Diagnosis of epilepsies](#)
- [Information and support](#)
- [New technologies](#)
- [Safety of antiseizure medications in women and girls](#)
- [Monitoring](#)
- [Therapeutic drug monitoring in women and girls](#)
- [Antiseizure medication for status epilepticus](#)
- [Antiseizure medications for repetitive/cluster seizures: monotherapy and add-on therapies](#)
- [Antiseizure medication for prolonged seizures: monotherapy](#)
- [Ketogenic diets for drug-resistant epilepsy](#)
- [Referral and surgical interventions](#)
- [Vagus nerve stimulation](#)
- [Prevalence of psychological disorders in people with epilepsies](#)
- [Psychological treatments for people with epilepsies](#)
- [Prediction of death, including SUDEP, in people with epilepsy](#)
- [Modifiable risk factors for epilepsy related mortality](#)
- [Reducing the risk of seizure-related mortality, including SUDEP](#)
- [Transition from paediatric to adult epilepsy services](#)
- [Magnetic resonance imaging scan to detect relevant abnormalities in people with epilepsy](#)
- [Computed tomography scan performance in people with epilepsy](#)
- [Effectiveness of genetic testing in determining the aetiology of epilepsy](#)
- [Antibody testing in epilepsy](#)
- [Monotherapy for generalised tonic-clonic and focal onset seizures](#)
- [Add-on therapy for generalised tonic-clonic and focal onset seizures](#)
- [Effectiveness of antiseizure therapies in the treatment of absence seizures](#)
- [Effectiveness of antiseizure therapies in the treatment of myoclonic seizures](#)
- [Effectiveness of antiseizure therapies in the treatment of tonic or atonic seizures/drop attacks](#)
- [Effectiveness of antiseizure therapies in the treatment of idiopathic generalised epilepsies, including juvenile myoclonic epilepsy](#)
- [Effectiveness of antiseizure therapies in the treatment of Dravet syndrome](#)
- [Effectiveness of antiseizure therapies in the treatment of Lennox-Gastaut syndrome](#)
- [Discontinuation of pharmacological treatment](#)
- [Criteria for referral to specialist services](#)

- [Effectiveness of a nurse specialist in the management of epilepsy](#)
- [Effectiveness of antiseizure therapies for infantile spasms](#)
- [Effectiveness of antiseizure medications for self-limited epilepsy with centrotemporal spikes](#)
- [Effectiveness of antiseizure therapies for epilepsy with myoclonic-atonic seizures \(Doose syndrome\)](#)

**Supplements:**

- [Methods \(NGA\)](#)
- [Methods \(NGC\)](#)
- [Health economics](#)
- [Cost effectiveness of antiseizure therapies for people with focal and generalised tonic-clonic seizures](#)
- [Cost effectiveness of resective epilepsy surgery in adults](#)